Investigational drug · Phase 2
SYS6023
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Breast Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "SYS6023"
First trial start
2026
May 25, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYS6023", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SYS6023" as an intervention, largest first.
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07110883 · 400 participants (planned) · Start Aug 15, 2024 · Primary completion Oct 31, 2026
Drug: SYS6023 · For: Advanced Solid Tumor
Sites: Harbin, China; Shanghai, China
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07597629 · 36 participants (planned) · Start May 25, 2026 · Primary completion Nov 30, 2027
Drug: SYS6023; KN026 · For: Advanced Breast Cancer
Sites: Harbin, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Breast Cancer
- AtirmociclibPF-07220060Phase 39 trials
Pfizer · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- UtidelonePhase 38 trials
Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma
- KN026PlacboPhase 37 trials
Shanghai JMT-Bio Inc. · HER2-positive Gastric Cancer, Advanced Breast Cancer, Resectable HER2-positive Breast Cancer
- PalazestrantOP-1250Phase 32 trials
Olema Oncology, Inc. · Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
- RYZ101Phase 32 trials
RayzeBio, Inc. · Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer
- XZP-3287Phase 32 trials
Xuanzhu Biopharmaceutical Co., Ltd. · Advanced Breast Cancer
- ZovegalisibPhase 31 trial
Relay Therapeutics, Inc. · PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor
- MHB039APhase 24 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Malignant Solid Tumor, Advanced Breast Cancer, Advanced Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.